Henry Schein (NASDAQ:HSIC) Stock Price Expected to Rise, Wells Fargo & Company Analyst Says

Henry Schein (NASDAQ:HSIC) had its price target hoisted by stock analysts at Wells Fargo & Company from $76.00 to $87.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage currently has an “equal weight” rating on the stock. Wells Fargo & Company‘s target price suggests a potential upside of 6.79% from the company’s current price.

A number of other brokerages have also recently issued reports on HSIC. Leerink Partners lifted their price objective on Henry Schein from $75.00 to $87.00 and gave the company a “market perform” rating in a report on Tuesday. Barclays initiated coverage on shares of Henry Schein in a research report on Monday, December 8th. They set an “overweight” rating and a $86.00 target price for the company. JPMorgan Chase & Co. boosted their price target on shares of Henry Schein from $76.00 to $78.00 and gave the company an “overweight” rating in a research report on Wednesday, November 5th. Mizuho set a $81.00 price objective on shares of Henry Schein and gave the stock a “neutral” rating in a report on Tuesday, January 20th. Finally, Morgan Stanley lifted their target price on shares of Henry Schein from $55.00 to $58.00 and gave the company an “underweight” rating in a research note on Wednesday, November 5th. Six investment analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, Henry Schein has a consensus rating of “Hold” and an average price target of $85.58.

Henry Schein Stock Down 0.5%

Shares of HSIC opened at $81.47 on Wednesday. The company has a quick ratio of 0.79, a current ratio of 1.38 and a debt-to-equity ratio of 0.59. The company has a 50-day moving average price of $77.75 and a two-hundred day moving average price of $72.04. The stock has a market cap of $9.34 billion, a price-to-earnings ratio of 24.91, a P/E/G ratio of 2.43 and a beta of 0.88. Henry Schein has a 12 month low of $60.56 and a 12 month high of $89.29.

Henry Schein (NASDAQ:HSIC) last issued its earnings results on Tuesday, February 24th. The company reported $1.34 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.30 by $0.04. The business had revenue of $3.44 billion during the quarter, compared to analysts’ expectations of $3.34 billion. Henry Schein had a return on equity of 15.16% and a net margin of 3.02%.Henry Schein’s quarterly revenue was up 7.7% compared to the same quarter last year. During the same period in the prior year, the firm posted $1.19 EPS. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. Equities analysts predict that Henry Schein will post 4.74 EPS for the current fiscal year.

Institutional Trading of Henry Schein

Several hedge funds have recently modified their holdings of the stock. MAI Capital Management increased its holdings in shares of Henry Schein by 7.5% in the third quarter. MAI Capital Management now owns 2,061 shares of the company’s stock valued at $137,000 after purchasing an additional 144 shares in the last quarter. CW Advisors LLC boosted its position in Henry Schein by 2.8% in the 2nd quarter. CW Advisors LLC now owns 5,913 shares of the company’s stock valued at $432,000 after buying an additional 163 shares during the last quarter. Truist Financial Corp increased its stake in shares of Henry Schein by 3.3% in the 3rd quarter. Truist Financial Corp now owns 5,540 shares of the company’s stock valued at $368,000 after buying an additional 175 shares during the period. Simon Quick Advisors LLC raised its position in shares of Henry Schein by 5.5% during the second quarter. Simon Quick Advisors LLC now owns 3,466 shares of the company’s stock worth $253,000 after acquiring an additional 182 shares during the last quarter. Finally, Claret Asset Management Corp lifted its stake in shares of Henry Schein by 6.3% during the second quarter. Claret Asset Management Corp now owns 3,173 shares of the company’s stock valued at $232,000 after acquiring an additional 187 shares during the period. 96.62% of the stock is owned by institutional investors.

Henry Schein News Summary

Here are the key news stories impacting Henry Schein this week:

• Positive Sentiment: Q4 beat and constructive outlook — Henry Schein beat EPS and revenue estimates, cited a stable dental market and set FY‑2026 EPS guidance (5.23–5.37), supporting the bullish narrative. Henry Schein beats quarterly profit estimates on stable dental market
• Positive Sentiment: Analyst upgrades and higher targets — Multiple firms raised price targets and ratings after results (notably JPMorgan to $92/overweight, UBS to $87, Mizuho/Wells Fargo lifts), signaling renewed conviction in growth and valuation support. These Analysts Increase Their Forecasts On Henry Schein After Upbeat Q4 Results
• Positive Sentiment: Independent upgrades/bullish research — Robert W. Baird upgraded HSIC and Leerink Partners published a forecast calling for strong price appreciation, adding to buying interest. Henry Schein (NASDAQ:HSIC) Upgraded at Robert W. Baird Leerink Partners Forecasts Strong Price Appreciation for Henry Schein (NASDAQ:HSIC) Stock
• Neutral Sentiment: Stock technical/market reaction — HSIC hit a 52‑week high on the post‑earnings rally, which can attract momentum flows but also profit‑taking. Henry Schein (NASDAQ:HSIC) Hits New 12-Month High on Earnings Beat
• Neutral Sentiment: Analysts reassessing story — Coverage notes that the company’s growth profile is changing and analysts are re-evaluating growth vs. valuation; this produces mixed revisions rather than uniform upgrades. How Henry Schein (HSIC) Story Is Shifting As Analysts Reassess Growth And Valuation
• Negative Sentiment: Sell‑side concerns remain — Morgan Stanley (and its analyst coverage reflected on TipRanks) continues to flag margin pressure and valuation as reasons for a Sell/underweight view with a low price target (~$58–$61), which limits consensus upside and can weigh on the stock. Henry Schein: Solid Growth but Margin Pressures and Valuation Drive Sell Rating
• Neutral Sentiment: Full Q4 transcript available for detail — Investors can review management commentary in the earnings transcript for guidance nuance and margin discussion. Henry Schein (HSIC) Q4 2025 Earnings Transcript

About Henry Schein

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.